|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1997-1-10
|
|
pubmed:abstractText |
The optimal dosage regimen for carbimazole (CBZ) in the treatment of hyperthyroidism remains uncertain, despite clinical use of the drug for approximately fifty years. We have compared the early clinical and biochemical responses to 20 or 40 mg/day of CBZ given as initial treatment for hyperthyroidism.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0300-0664
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
45
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
511-6
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8977745-Adolescent,
pubmed-meshheading:8977745-Adult,
pubmed-meshheading:8977745-Aged,
pubmed-meshheading:8977745-Antithyroid Agents,
pubmed-meshheading:8977745-Carbimazole,
pubmed-meshheading:8977745-Drug Administration Schedule,
pubmed-meshheading:8977745-Humans,
pubmed-meshheading:8977745-Hyperthyroidism,
pubmed-meshheading:8977745-Hypothyroidism,
pubmed-meshheading:8977745-Middle Aged,
pubmed-meshheading:8977745-Prospective Studies,
pubmed-meshheading:8977745-Thyroxine,
pubmed-meshheading:8977745-Triiodothyronine
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
A comparison of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism.
|
|
pubmed:affiliation |
Department of Diabetes and Endocrinology, City Hospital, Nottingham, UK.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study
|
